Vor Bio announced on July 10, 2025, the appointment of Sandy Mahatme as Chief Financial Officer and Chief Business Officer, effective July 9, 2025. Mr. Mahatme brings over 30 years of executive leadership experience in the biopharmaceutical industry, with a strong track record in capital markets, business development, global operations, and shareholder value creation.
His previous roles include President, Chief Operating Officer, and Chief Financial Officer of National Resilience, Inc., where he co-founded the company and raised over $2.5 billion in capital. He also served as Executive Vice President, Chief Financial Officer, and Chief Business Officer of Sarepta Therapeutics, leading capital formation efforts exceeding $3.5 billion.
Mr. Mahatme's financial acumen and experience in navigating strategic growth are expected to be instrumental as Vor Bio advances telitacicept through global Phase 3 development and pursues its mission in autoimmune diseases. In connection with his appointment, Mr. Mahatme received an inducement grant of 13,882,750 restricted stock units.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.